14 Chapter 13Table 13.1 Genetic alterations as biomarkers.
15 Chapter 13Table 13.2 SMYD overexpression as biomarker.
16 Chapter 13Table 13.3 SMYD3-mediated histone lysine methylation as biomarker.
17 Chapter 13Table 13.4 Non-histone lysine methylation as biomarker.
18 Chapter 14Table 14.1 Summary of the main risk factors...
19 Chapter 14Table 14.2 Types of immunotherapies currently...
20 Chapter 15Table 15.1 DMTs subtypes and their function.
21 Chapter 15Table 15.2 Epigenetic interference of food...
22 Chapter 16Table 16.1 Toxic effects associated to...
23 Chapter 17Table 17.1 List of candidate genes involved in the...
24 Chapter 18Table 18.1 Summary of differentially methylated clusters.
25 Chapter 20Table 20.1 A summary of selected nanomaterial...
26 Chapter 20Table 20.2 Hallmark features of nanoparticle...
Guide
1 Cover
5 Table of Contents
6 Preface
10 Index
Pages
1 i
2 ii
3 iii
4 iv
5 v
6 vi
7 vii
8 viii
9 ix
10 xi
11 xiii
12 xv
13 xvi
14 xvii
15 xviii
16 1
17 2
18 3
19 4
20 5
21 6
22 7
23 8
24 9
25 10
26 11
27 12
28 13
29 14
30 15
31 16
32 17
33 18
34 19
35 20
36 21
37 22
38 23
39 24
40 25
41 26
42 27
43 28
44 29
45 30
46 31
47 32
48 33
49 34
50 35
51 36
52 37
53 38